Search research articles
Contact Us
Filters
Showing results (21-30 of 37) with videos related to
Page
of 4
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging
|
July 1, 2025
Biodistribution of free Francium-221 and Bismuth-213 in Tumour-bearing SCID mice after successful development of Actinium-225/Francium-221 radionuclide generator Set-up
Sabine Zitzmann-Kolbe, Yvonne Remde, Ingrid Moen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 10, 2019
Synergistic Effect of a Mesothelin-Targeted <sup>227</sup>Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models
Katrine Wickstroem, Urs B Hagemann, Véronique Cruciani, et al.
Cancers
|
July 14, 2023
Efficacy of a HER2-Targeted Thorium-227 Conjugate in a HER2-Positive Breast Cancer Bone Metastasis Model
Jenny Karlsson, Urs B Hagemann, Véronique Cruciani, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
May 20, 2021
<i>In Vitro</i> and <i>In Vivo</i> Comparison of 3,2-HOPO Versus Deferoxamine-Based Chelation of Zirconium-89 to the Antimesothelin Antibody Anetumab
Jyoti Roy, Elaine M Jagoda, Falguni Basuli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 26, 2021
Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models
Stefanie Hammer, Andreas Schlicker, Sabine Zitzmann-Kolbe, et al.
Molecular Cancer Therapeutics
|
June 26, 2023
A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic Therapies
Sabine Zitzmann-Kolbe, Alexander Kristian, Dieter Zopf, et al.
The Journal of Clinical Investigation
|
January 31, 2017
A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer
Chiara Berlato, Moddasar N Khan, Tiziana Schioppa, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 1, 2019
Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344
Katrine Wickstroem, Urs B Hagemann, Alexander Kristian, et al.
Molecular Pharmaceutics
|
March 3, 2026
Investigation of Radiolabeled KISS1R Ligands as Promising Tools for Diagnosis and Treatment of Triple-Negative Breast Cancer
Harun Taş, Martin Schäfer, Aneeba Shuja-Uddin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 14, 2019
Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer
Stefanie Hammer, Urs B Hagemann, Sabine Zitzmann-Kolbe, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 37) with videos related to
Sort By:
Page
of 4
European Journal of Nuclear Medicine and Molecular Imaging
|
July 1, 2025
Biodistribution of free Francium-221 and Bismuth-213 in Tumour-bearing SCID mice after successful development of Actinium-225/Francium-221 radionuclide generator Set-up
Sabine Zitzmann-Kolbe, Yvonne Remde, Ingrid Moen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 10, 2019
Synergistic Effect of a Mesothelin-Targeted <sup>227</sup>Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models
Katrine Wickstroem, Urs B Hagemann, Véronique Cruciani, et al.
Cancers
|
July 14, 2023
Efficacy of a HER2-Targeted Thorium-227 Conjugate in a HER2-Positive Breast Cancer Bone Metastasis Model
Jenny Karlsson, Urs B Hagemann, Véronique Cruciani, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
May 20, 2021
<i>In Vitro</i> and <i>In Vivo</i> Comparison of 3,2-HOPO Versus Deferoxamine-Based Chelation of Zirconium-89 to the Antimesothelin Antibody Anetumab
Jyoti Roy, Elaine M Jagoda, Falguni Basuli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 26, 2021
Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models
Stefanie Hammer, Andreas Schlicker, Sabine Zitzmann-Kolbe, et al.
Molecular Cancer Therapeutics
|
June 26, 2023
A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic Therapies
Sabine Zitzmann-Kolbe, Alexander Kristian, Dieter Zopf, et al.
The Journal of Clinical Investigation
|
January 31, 2017
A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer
Chiara Berlato, Moddasar N Khan, Tiziana Schioppa, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 1, 2019
Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344
Katrine Wickstroem, Urs B Hagemann, Alexander Kristian, et al.
Molecular Pharmaceutics
|
March 3, 2026
Investigation of Radiolabeled KISS1R Ligands as Promising Tools for Diagnosis and Treatment of Triple-Negative Breast Cancer
Harun Taş, Martin Schäfer, Aneeba Shuja-Uddin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 14, 2019
Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer
Stefanie Hammer, Urs B Hagemann, Sabine Zitzmann-Kolbe, et al.
Page
of 4